Is CTABF or MRK a better dividend investment in 2026?

CTABF currently yields 2000000.00% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: CTABF offers higher current income.

What is the dividend yield difference between CTABF and MRK?

CTABF has a forward dividend yield of 2000000.00% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 1999997.24 percentage points.

Home › Compare › CTABF vs MRK

CTABF vs MRK: Dividend Comparison 2026

CTABF yields 2000000.00% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CTABF wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CTABF

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full CTABF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — CTABF vs MRK

📍 CTABF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CTABF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CTABF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CTABF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTABF

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, CTABF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTABF + MRK for your $10,000?

CTABF: 50%MRK: 50%

100% MRK50/50100% CTABF

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CTABF

No analyst data

Altman Z

-39.5

Piotroski

3/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTABF buys

MRK buys

No recent congressional trades found for CTABF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCTABFMRK

Forward yield	2000000.00% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$4.879226400974806e+39M	$56.8K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$9,798.13
Total dividends collected	$4.879195005460081e+39M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: CTABF vs MRK ($10,000, DRIP)

Year	CTABF Portfolio	CTABF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,206	$366.19	+$200.00M → CTABF
2	$3,738,731,768,458	$3,738,517,757,009.35	$12,650	$502.35	+$3738731.76M → CTABF
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$14,407	$694.19	+$65315062866.92M → CTABF
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$16,585	$967.82	+$1066400830062625.00M → CTABF
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$19,342	$1,363.89	+$16272182796453826560.00M → CTABF
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$22,913	$1,947.19	+$2.3205424011366188e+23M → CTABF
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$27,662	$2,823.89	+$3.0927990661046884e+27M → CTABF
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$34,159	$4,173.35	+$3.8524105697352695e+31M → CTABF
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$43,337	$6,308.80	+$4.484688260147987e+35M → CTABF
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$56,776	$9,798.13	+$4.879226400974806e+39M → CTABF

CTABF vs MRK: Complete Analysis 2026

CTABF — Stock

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

Full CTABF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this CTABF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTABF vs SCHD CTABF vs JEPI CTABF vs O CTABF vs KO CTABF vs MAIN CTABF vs JNJ CTABF vs ABBV CTABF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.